These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27364549)

  • 61. Controlled-release carvedilol in the treatment of essential hypertension.
    Weber MA; Sica DA; Tarka EA; Iyengar M; Fleck R; Bakris GL
    Am J Cardiol; 2006 Oct; 98(7A):32L-38L. PubMed ID: 17023230
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sinus rhythm versus atrial fibrillation in elderly patients with chronic heart failure--insight from the Cardiac Insufficiency Bisoprolol Study in Elderly.
    Stankovic I; Neskovic AN; Putnikovic B; Apostolovic S; Lainscak M; Edelmann F; Doehner W; Gelbrich G; Inkrot S; Rau T; Herrmann-Lingen C; Anker SD; Düngen HD
    Int J Cardiol; 2012 Nov; 161(3):160-5. PubMed ID: 22726401
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial).
    Figulla HR; Krzeminska-Pakula M; Wrabec K; Chochola J; Kalmbach C; Fridl P
    Int J Cardiol; 2006 Nov; 113(2):153-60. PubMed ID: 16157399
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacodynamics of carvedilol in conscious, healthy dogs.
    Gordon SG; Arsenault WG; Longnecker M; Boothe DM; Miller MW; Chalkley J
    J Vet Intern Med; 2006; 20(2):297-304. PubMed ID: 16594586
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
    Lainscak M; Podbregar M; Kovacic D; Rozman J; von Haehling S
    Respir Med; 2011 Oct; 105 Suppl 1():S44-9. PubMed ID: 22015086
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN; Mangal B
    BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program.
    Joglar JA; Acusta AP; Shusterman NH; Ramaswamy K; Kowal RC; Barbera SJ; Hamdan MH; Page RL
    Am Heart J; 2001 Sep; 142(3):498-501. PubMed ID: 11526364
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
    Roy D; Rowe BH; Stiell IG; Coutu B; Ip JH; Phaneuf D; Lee J; Vidaillet H; Dickinson G; Grant S; Ezrin AM; Beatch GN;
    J Am Coll Cardiol; 2004 Dec; 44(12):2355-61. PubMed ID: 15607398
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
    Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
    Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
    Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [The effects of mid- and long-term administration (3-4 years) of carvedilol in patients with idiopathic dilated cardiomyopathy].
    Metra M; Nodari S; Garbellini M; Boldi E; Rosselli F; Milan E; Giubbini R; Dei Cas L
    Cardiologia; 1997 May; 42(5):503-12. PubMed ID: 9289367
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.
    Swedberg K; Olsson LG; Charlesworth A; Cleland J; Hanrath P; Komajda M; Metra M; Torp-Pedersen C; Poole-Wilson P
    Eur Heart J; 2005 Jul; 26(13):1303-8. PubMed ID: 15767288
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial.
    Contini M; Apostolo A; Cattadori G; Paolillo S; Iorio A; Bertella E; Salvioni E; Alimento M; Farina S; Palermo P; Loguercio M; Mantegazza V; Karsten M; Sciomer S; Magrì D; Fiorentini C; Agostoni P
    Int J Cardiol; 2013 Oct; 168(3):2134-40. PubMed ID: 23506636
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Benefits of prescribing low-dose digoxin in atrial fibrillation.
    Rosca CI; Kundnani NR; Tudor A; Rosca MS; Nicoras VA; Otiman G; Ciurariu E; Ionescu A; Stelian M; Sharma A; Borza C; Lighezan DF
    Int J Immunopathol Pharmacol; 2021; 35():20587384211051955. PubMed ID: 34724841
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation.
    Ishiguro H; Ikeda T; Abe A; Tsukada T; Mera H; Nakamura K; Yusu S; Yoshino H
    Int Heart J; 2008 May; 49(3):281-93. PubMed ID: 18612186
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dual chamber pacing in patients with severe heart failure on beta blocker and amiodarone treatment: preliminary results of a randomised study.
    Nägele H; Schomburg R; Petersen B; Rödiger W
    Heart; 2002 Jun; 87(6):566-7. PubMed ID: 12010943
    [No Abstract]   [Full Text] [Related]  

  • 78. Hemodynamic and metabolic effects of carvedilol: a meta-analysis approach.
    Stienen U; Meyer-Sabellek W
    Clin Investig; 1992; 70 Suppl 1():S65-72. PubMed ID: 1350487
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Differential Response to Heart Rate Reduction by Carvedilol in Heart Failure and Reduced Ejection Fraction Between Sinus Rhythm and Atrial Fibrillation　- Insight From J-CHF Study.
    Nagatomo Y; Yoshikawa T; Okamoto H; Kitabatake A; Hori M;
    Circ Rep; 2020 Mar; 2(3):143-151. PubMed ID: 33693221
    [No Abstract]   [Full Text] [Related]  

  • 80. Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation.
    Campodonico J; Piepoli M; Clemenza F; Bonomi A; Paolillo S; Salvioni E; Corrà U; Binno S; Veglia F; Lagioia R; Sinagra G; Cattadori G; Scardovi AB; Metra M; Senni M; Scrutinio D; Raimondo R; Emdin M; Magrì D; Parati G; Re F; Cicoira M; Minà C; Limongelli G; Correale M; Frigerio M; Bussotti M; Perna E; Battaia E; Guazzi M; Badagliacca R; Di Lenarda A; Maggioni A; Passino C; Sciomer S; Pacileo G; Mapelli M; Vignati C; Lombardi C; Filardi PP; Agostoni P;
    Int J Cardiol; 2018 Dec; 273():141-146. PubMed ID: 30098827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.